INGN Stock Overview
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Inogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.05 |
| 52 Week High | US$14.10 |
| 52 Week Low | US$4.13 |
| Beta | 1.08 |
| 1 Month Change | -6.25% |
| 3 Month Change | 25.00% |
| 1 Year Change | -45.94% |
| 3 Year Change | -89.41% |
| 5 Year Change | -91.79% |
| Change since IPO | -53.47% |
Recent News & Updates
Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities
Apr 13Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target
Mar 01
Recent updates
Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities
Apr 13Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target
Mar 01Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%
Feb 01Is Inogen (NASDAQ:INGN) In A Good Position To Deliver On Growth Plans?
Oct 06Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business
Jun 21Is Inogen, Inc. (NASDAQ:INGN) Worth US$13.3 Based On Its Intrinsic Value?
Mar 14Companies Like Inogen (NASDAQ:INGN) Can Afford To Invest In Growth
Oct 27Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price
Sep 20Inogen: Structural, Supply Chain Headwinds Remain
Sep 13Inogen Non-GAAP EPS of -$0.02 beats by $0.31, revenue of $103.38M beats by $2.74M
Aug 04Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds
Jun 14At US$35.28, Is It Time To Put Inogen, Inc. (NASDAQ:INGN) On Your Watch List?
Apr 03Hammered By Supply Issues, Inogen Could Be A 2023 Comeback Story
Mar 31Is There An Opportunity With Inogen, Inc.'s (NASDAQ:INGN) 28% Undervaluation?
Mar 09Inogen: Capacity Constraints Cloud Post Pandemic Potential
Jan 06Is Inogen, Inc. (NASDAQ:INGN) Potentially Undervalued?
Dec 09Returns On Capital At Inogen (NASDAQ:INGN) Paint A Concerning Picture
Nov 08Supply Chain Issues Knock Inogen Back, But Underlying Growth Is Encouraging
Aug 30Shareholder Returns
| INGN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.4% | 1.8% | 1.2% |
| 1Y | -45.9% | -0.5% | 24.9% |
Return vs Industry: INGN underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: INGN underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| INGN volatility | |
|---|---|
| INGN Average Weekly Movement | 15.7% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INGN's share price has been volatile over the past 3 months.
Volatility Over Time: INGN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 834 | Kevin R. Smith | www.inogen.com |
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.
Inogen, Inc. Fundamentals Summary
| INGN fundamental statistics | |
|---|---|
| Market cap | US$162.47m |
| Earnings (TTM) | -US$102.45m |
| Revenue (TTM) | US$315.66m |
0.5x
P/S Ratio-1.6x
P/E RatioIs INGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INGN income statement (TTM) | |
|---|---|
| Revenue | US$315.66m |
| Cost of Revenue | US$188.96m |
| Gross Profit | US$126.70m |
| Other Expenses | US$229.15m |
| Earnings | -US$102.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -4.35 |
| Gross Margin | 40.14% |
| Net Profit Margin | -32.46% |
| Debt/Equity Ratio | 0% |
How did INGN perform over the long term?
See historical performance and comparison